Bank of Montreal Can lowered its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 61.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 256,796 shares of the biopharmaceutical company’s stock after selling 412,513 shares during the period. Bank of Montreal Can owned 0.12% of Alexion Pharmaceuticals worth $35,696,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Gradient Investments LLC boosted its stake in Alexion Pharmaceuticals by 37.3% during the 3rd quarter. Gradient Investments LLC now owns 8,256 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 2,242 shares during the period. Vigilant Capital Management LLC boosted its stake in Alexion Pharmaceuticals by 24.5% during the 3rd quarter. Vigilant Capital Management LLC now owns 107,720 shares of the biopharmaceutical company’s stock worth $14,974,000 after purchasing an additional 21,180 shares during the period. Arrow Financial Corp acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $278,000. DNB Asset Management AS boosted its stake in Alexion Pharmaceuticals by 3.7% during the 3rd quarter. DNB Asset Management AS now owns 27,175 shares of the biopharmaceutical company’s stock worth $3,778,000 after purchasing an additional 967 shares during the period. Finally, Factory Mutual Insurance Co. boosted its stake in Alexion Pharmaceuticals by 11.9% during the 3rd quarter. Factory Mutual Insurance Co. now owns 665,300 shares of the biopharmaceutical company’s stock worth $92,483,000 after purchasing an additional 70,900 shares during the period. Hedge funds and other institutional investors own 93.06% of the company’s stock.

Shares of ALXN opened at $126.56 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.72 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $30.98 billion, a PE ratio of 24.88, a P/E/G ratio of 1.27 and a beta of 0.79. Alexion Pharmaceuticals, Inc. has a 52-week low of $102.10 and a 52-week high of $142.24.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.58. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The business’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.56 EPS. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current fiscal year.

Several research firms have recently commented on ALXN. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Barclays raised their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Evercore ISI restated an “outperform” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, July 26th. JPMorgan Chase & Co. raised their target price on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the stock an “overweight” rating in a research note on Friday, July 27th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $123.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $160.74.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Further Reading: Return on Investment (ROI) Defined, Explained

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.